A Study to Assess Growth in Children With Idiopathic Short Stature
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- BioMarin Pharmaceutical
- Study ID
- NCT06309979
- Status
- Recruiting
Conditions
- Idiopathic Short Stature
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 16 Years
- Healthy Volunteers
- Not accepted
Study Details
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Key Dates
- First listed
- Mar 13, 2024
- Start date
- Aug 8, 2024
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2040
- Completion
- Dec 31, 2040
Study Design
- Enrollment
- 300 participants (estimated)
Primary Outcome Measure
Change in annualized growth velocity (AGV) [ Time Frame: Every 6 months through end of study, up to 15 years ]
Central Contacts
- Trial Specialist18009834587
Locations (38)
Find similar trials in Phoenix, AZ
By research site
Phoenix Children's Hospital - Thomas Campus (Main)· Phoenix, AZChildren's Hospital Los Angeles· Los Angeles, CAHarbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed)· Los Angeles, CAChildren's Hospital of Orange County Main Campus - Orange· Orange, CACenter Of Excellence in Diabetes and Endocrinology· Sacramento, CARady Children's Hospital - San Diego· San Diego, CA
Related Studies
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short StaturePHASE2 · Recruiting · BioMarin Pharmaceutical · California City, California
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersPHASE3 · Recruiting · Ascendis Pharma A/S · Palo Alto, California